
Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (GLSI) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · GLSI · as of Jun 9, 2026
Activity summary
Buy transactions
17
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Greenwich LifeSciences, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
GLSI insider buying and selling by quarter
GLSI insider selling · GLSI insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · GLSI ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
GLSI executive sell shares · GLSI board member insider trading · GLSI insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jan 13, 2026 | Patel Snehal CEO and CFO · Director | Purchase | 1,800 | $54K | Form 4 |
| Jan 12, 2026 | Patel Snehal CEO and CFO · Director | Purchase | 2,900 | $80K | Form 4 |
| Dec 31, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 4,300 | $92K | Form 4 |
| Dec 30, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 2,900 | $63K | Form 4 |
| Dec 18, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 4,100 | $52K | Form 4 |
| Nov 25, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 4,600 | $39K | Form 4 |
| Nov 7, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 10,600 | $89K | Form 4 |
| Oct 31, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 2,300 | $21K | Form 4 |
| Apr 25, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 3,600 | $36K | Form 4 |
| Apr 17, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 5,400 | $48K | Form 4 |
| Apr 7, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 3,600 | $33K | Form 4 |
| Apr 4, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 5,500 | $48K | Form 4 |
| Jan 10, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 2,500 | $31K | Form 4 |
| Jan 7, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 1,800 | $25K | Form 4 |
| Jan 6, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 1,100 | $15K | Form 4 |
| Jan 3, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 3,400 | $44K | Form 4 |
| Jan 2, 2025 | Patel Snehal CEO and CFO · Director | Purchase | 2,000 | $24K | Form 4 |
| Dec 31, 2024 | Patel Snehal CEO and CFO · Director | Purchase | 2,400 | $27K | Form 4 |
| Dec 30, 2024 | Patel Snehal CEO and CFO · Director | Purchase | 3,200 | $36K | Form 4 |
| Nov 21, 2024 | Thompson Jaye VP Clinical Reg Affairs | Purchase | 1,000 | $13K | Form 4 |
| Sep 26, 2024 | Patel Snehal CEO and CFO · Director | Purchase | 1,500 | $22K | Form 4 |
| Aug 12, 2024 | Thompson Jaye VP Clinical Reg Affairs | Purchase | 800 | $11K | Form 4 |
| Aug 6, 2024 | Patel Snehal CEO and CFO · Director | Purchase | 2,000 | $28K | Form 4 |
| Aug 5, 2024 | Patel Snehal CEO and CFO · Director | Purchase | 5,500 | $72K | Form 4 |
| Aug 2, 2024 | Thompson Jaye VP Clinical Reg Affairs | Purchase | 1,000 | $15K | Form 4 |
Patel Snehal
CEO and CFO · Director
Date
Jan 13
Shares
1,800
Price
$29.83
Value
$54K
Patel Snehal
CEO and CFO · Director
Date
Jan 12
Shares
2,900
Price
$27.54
Value
$80K
Patel Snehal
CEO and CFO · Director
Date
Dec 31
Shares
4,300
Price
$21.36
Value
$92K
Patel Snehal
CEO and CFO · Director
Date
Dec 30
Shares
2,900
Price
$21.73
Value
$63K
Patel Snehal
CEO and CFO · Director
Date
Dec 18
Shares
4,100
Price
$12.62
Value
$52K
Patel Snehal
CEO and CFO · Director
Date
Nov 25
Shares
4,600
Price
$8.37
Value
$39K
Patel Snehal
CEO and CFO · Director
Date
Nov 7
Shares
10,600
Price
$8.43
Value
$89K
Patel Snehal
CEO and CFO · Director
Date
Oct 31
Shares
2,300
Price
$9.26
Value
$21K
Patel Snehal
CEO and CFO · Director
Date
Apr 25
Shares
3,600
Price
$9.88
Value
$36K
Patel Snehal
CEO and CFO · Director
Date
Apr 17
Shares
5,400
Price
$8.98
Value
$48K
Patel Snehal
CEO and CFO · Director
Date
Apr 7
Shares
3,600
Price
$9.10
Value
$33K
Patel Snehal
CEO and CFO · Director
Date
Apr 4
Shares
5,500
Price
$8.73
Value
$48K
Patel Snehal
CEO and CFO · Director
Date
Jan 10
Shares
2,500
Price
$12.51
Value
$31K
Patel Snehal
CEO and CFO · Director
Date
Jan 7
Shares
1,800
Price
$13.75
Value
$25K
Patel Snehal
CEO and CFO · Director
Date
Jan 6
Shares
1,100
Price
$13.31
Value
$15K
Patel Snehal
CEO and CFO · Director
Date
Jan 3
Shares
3,400
Price
$12.95
Value
$44K
Patel Snehal
CEO and CFO · Director
Date
Jan 2
Shares
2,000
Price
$11.97
Value
$24K
Patel Snehal
CEO and CFO · Director
Date
Dec 31
Shares
2,400
Price
$11.36
Value
$27K
Patel Snehal
CEO and CFO · Director
Date
Dec 30
Shares
3,200
Price
$11.12
Value
$36K
Thompson Jaye
VP Clinical Reg Affairs
Date
Nov 21
Shares
1,000
Price
$12.91
Value
$13K
Patel Snehal
CEO and CFO · Director
Date
Sep 26
Shares
1,500
Price
$14.63
Value
$22K
Thompson Jaye
VP Clinical Reg Affairs
Date
Aug 12
Shares
800
Price
$13.85
Value
$11K
Patel Snehal
CEO and CFO · Director
Date
Aug 6
Shares
2,000
Price
$13.81
Value
$28K
Patel Snehal
CEO and CFO · Director
Date
Aug 5
Shares
5,500
Price
$13.18
Value
$72K
Thompson Jaye
VP Clinical Reg Affairs
Date
Aug 2
Shares
1,000
Price
$15.15
Value
$15K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About GLSI insider trading
GLSI insider trades
Greenwich LifeSciences, Inc. (GLSI) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Patel Snehal (CEO and CFO · Director). Over the past 12 months, 1 insiders have filed transactions with the SEC. GLSI insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Greenwich LifeSciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
GLSI insider trading · 5 questionsThe insiders of Greenwich LifeSciences, Inc. (GLSI) include executives and directors such as Patel Snehal (CEO and CFO · Director), among others. Over the past 12 months, 1 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026